Objective: Extensive stage Small-Cell Lung Cancer (ES-SCLC) is the most lethal lung cancer, and the addition of immunotherapy conferred a slight survival benefit for patients. Extensive molecular profiling of patients treated with chemotherapy (CT) or chemotherapy plus immunotherapy (CT+IO) would be able to identify molecular factors associated with patients' survival.
Material And Methods: In this retrospective study, 99 ES-SCLC patients were considered. Of the 79 includible patients, 42 received CT (median age 71 y/o, I-IIIQ: 65-76), and 37 received CT+IO (median age 71 y/o, I-IIIQ 66-75). The FoundationOne CDx assay was performed on patients' tumor tissues.
Results: The most mutated genes were (99%), (78%), (23%) and (20%), with no significant differences between the treatment groups. As a continuous variable, Tumor Mutation Burden (TMB) had an effect on patients' progression-free survival (PFS) by type of treatment (HR 1.81 (95%, CI: 0.99-3.31) and HR 0.84 (95%, CI: 0.56-1.26) for patients treated with CT and CT+IO, respectively). TMB was also computed and dichotomized using two different cut-offs: considering cut-offs of 10 mut/Mb and >16 mut/Mb, 45 patients (57%) and 68 patients (86.1%) had a low TMB, respectively. A high TMB (cut-off 10 mut/Mb) predicted worse PFS in patients treated with CT (=0.046); even though not statistically significant, a high TMB (cut-off 16 mut/Mb) predicted a better survival in patients treated with CT+IO. Moreover, at univariate analysis, mutations were associated with better prognosis in the overall case series (HR = 0.51, 95% CI: 0.28-0.94), and overall survival (HR = 0.52, 95% CI: 0.28-0.97).
Conclusion: In ES-SCLC, TMB is associated with worse survival in patients treated with CT alone, and with better survival in patients treated with CT+IO, whether considered as a continuous or a dichotomized variable, at different cut-offs. Alterations in epigenetic factors are also associated to better patient prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849429 | PMC |
| http://dx.doi.org/10.2147/LCTT.S492825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.
J Cutan Med Surg
March 2025
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes of cutaneous T-cell lymphoma with numerous topical and systemic therapies. Early-stage MF can be managed with topical corticosteroids, mechlorethamine, and phototherapy. However, patients are often non-responsive to topical therapies, thus requiring systemic therapies.
View Article and Find Full Text PDFOccupational Therapy Pre-Operative Intervention for Total Hip Replacement Patients; A Qualitative Enquiry.
Occup Ther Health Care
March 2025
Physiotherapy Research Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
This project aimed to explore the experiences of occupational therapists working in a specialist orthopedic hospital. Semi-structured interviews were carried out with eight occupational therapists working with total hip replacement patients, in an orthopedic hospital within the United Kingdom National Health Service (NHS) as part of a service review project. The data was recorded and transcribed and analyzed using the Reflexive Thematic Analysis.
View Article and Find Full Text PDFPatient Eczema Education Pictorial Study (PEEPS): A Pilot Investigation.
J Cutan Med Surg
March 2025
Division of Dermatology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Background: For optimal control of atopic dermatitis (AD), patient education is essential to complement traditional therapy. Patient education has proven to benefit AD outcomes, but previous methods of delivery are costly and time-consuming.
Objective: To assess the effectiveness of a one-page pictorial education tool at improving AD quality of life (QoL) and disease severity.
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.
Epilepsia
March 2025
University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.
Objective: We analyzed the long-term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open-label extension (OLE) study after participating in randomized controlled trials (RCTs) or commencing FFA de novo as adults.
Methods: Patients with DS who participated in one of three RCTs or were 19 to 35 years of age and started FFA de novo were included. Key endpoints were: incidence of treatment-emergent adverse events (TEAEs) in the safety population, and median percentage change in monthly convulsive seizure frequency (MCSF) from the RCT baseline to end of study (EOS) in the modified intent-to-treat (mITT) population.
Survey of the impact of BOLT-trial data on oncologists' and dermatologists' decision-making in treating patients with locally advanced basal cell carcinoma.
Dermatol Reports
February 2025
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples.
Basal cell carcinoma (BCC) is the most common malignant tumor in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic target. In Italy, clinicians can prescribe Hedgehog inhibitors (HhIs) vismodegib and sonidegib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!